Evidence map›Paper›PMID 30456329›Full record

ArticleJACC. Basic to translational science2018

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.

Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719714 (Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease), which is not on this map. Cited by 205 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 2 pooled it
27.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719714 phase1 / phase2active not recruitingstarted 2024, after this paper: background citation

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Ran2024Enrolled18Registered outcomes5Posted comparisons0ConditionsChronic Kidney Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Kidney DiseasesArmsDapagliflozin 10 MG [Farxiga]
PMID 29166232PMID 29526832PMID 29133604PMID 3361755PMID 10716471PMID 15504931PMID 16461840PMID 18760751PMID 21262990PMID 21817129PMID 24218128PMID 25370599other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 2 syntheses or guidelines pooled it, 366 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. ELUCIDATE Trial: A Single-Center Randomized Controlled Study.Journal of the American Heart Association · 2024
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Subodh VermaDivision of Cardiac Surgery, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
Sonia RawatCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
Kim L HoCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
Cory S WaggCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
Liyan ZhangCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
Hwee TeohDivision of Cardiac Surgery, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
John E DyckCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
Golam M UddinCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
Gavin Y OuditCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
Eric MayouxBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Michael LehrkeDepartment of Internal Medicine I-Cardiology, University Hospital Aachen, Aachen, Germany.
Nikolaus MarxDepartment of Internal Medicine I-Cardiology, University Hospital Aachen, Aachen, Germany.
Gary D LopaschukCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
University of Alberta · CASt. Michael's Hospital · CAUniversitätsklinikum Aachen · DEBoehringer Ingelheim (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SGLT2 inhibitors have profound benefits on reducing heart failure and cardiovascular mortality in individuals with type 2 diabetes, although the mechanism(s) of this benefit remain poorly understood. Because changes in cardiac bioenergetics play a critical role in the pathophysiology of heart failure, the authors evaluated cardiac energy production and substrate use in diabetic mice treated with the SGTL2 inhibitor, empagliflozin. Empagliflozin treatment of diabetic

Indexed as

ANOVA, analysis of varianceATP, adenosine triphosphatecardiac efficiencydb/dbglucose oxidationketone oxidationLV, left ventricularPDH, pyruvate-dehydrogenaseßOHB, β-hydroxybutyrate

Identifiers

PMID30456329
PMCPMC6234616
OpenAlexW2888544493

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.